126 related articles for article (PubMed ID: 38673931)
21. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
22. Semaglutide once-weekly: improved efficacy with a new safety warning.
Coon SA; Crannage EF; Kerwin LC; Guyton JE
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Li J; He K; Ge J; Li C; Jing Z
Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
[TBL] [Abstract][Full Text] [Related]
24. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
25. Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future.
O'Neill ES; Wiegmann AL; Parrella N; Pittman T; Hood K; Kurlander D
Plast Reconstr Surg Glob Open; 2024 Jan; 12(1):e5516. PubMed ID: 38268718
[TBL] [Abstract][Full Text] [Related]
26. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
Silverii GA; Monami M; Gallo M; Ragni A; Prattichizzo F; Renzelli V; Ceriello A; Mannucci E
Diabetes Obes Metab; 2024 Mar; 26(3):891-900. PubMed ID: 38018310
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management.
Wojtara M; Mazumder A; Syeda Y; Mozgała N
Adv Med; 2023; 2023():9946924. PubMed ID: 37771634
[TBL] [Abstract][Full Text] [Related]
28. Semaglutide and cancer: A systematic review and meta-analysis.
Nagendra L; Bg H; Sharma M; Dutta D
Diabetes Metab Syndr; 2023 Sep; 17(9):102834. PubMed ID: 37531876
[TBL] [Abstract][Full Text] [Related]
29. Sex-Related Differences in the Pharmacological Response in SARS-CoV-2 Infection, Dyslipidemia, and Diabetes Mellitus: A Narrative Review.
Lombrea A; Romanescu M; Jianu N; Andor M; Suciu M; Man DE; Danciu C; Dehelean CA; Buda V
Pharmaceuticals (Basel); 2023 Jun; 16(6):. PubMed ID: 37375800
[TBL] [Abstract][Full Text] [Related]
30. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Loomba R; Abdelmalek MF; Armstrong MJ; Jara M; Kjær MS; Krarup N; Lawitz E; Ratziu V; Sanyal AJ; Schattenberg JM; Newsome PN;
Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):511-522. PubMed ID: 36934740
[TBL] [Abstract][Full Text] [Related]
31. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations.
Chao AM; Tronieri JS; Amaro A; Wadden TA
Drug Des Devel Ther; 2022; 16():4449-4461. PubMed ID: 36601368
[TBL] [Abstract][Full Text] [Related]
32. In Vitro and In Silico Evaluation of the Antimicrobial and Antioxidant Potential of
Jianu C; Rusu LC; Muntean I; Cocan I; Lukinich-Gruia AT; Goleț I; Horhat D; Mioc M; Mioc A; Șoica C; Bujancă G; Ilie AC; Muntean D
Antioxidants (Basel); 2022 Dec; 11(12):. PubMed ID: 36552681
[TBL] [Abstract][Full Text] [Related]
33. Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts.
Thompson CA; Stürmer T
Diabetes Care; 2023 Feb; 46(2):249-251. PubMed ID: 36525594
[No Abstract] [Full Text] [Related]
34. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.
Yang Z; Lv Y; Yu M; Mei M; Xiang L; Zhao S; Li R
Front Pharmacol; 2022; 13():925377. PubMed ID: 36386208
[No Abstract] [Full Text] [Related]
35. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
Bezin J; Gouverneur A; Pénichon M; Mathieu C; Garrel R; Hillaire-Buys D; Pariente A; Faillie JL
Diabetes Care; 2023 Feb; 46(2):384-390. PubMed ID: 36356111
[TBL] [Abstract][Full Text] [Related]
36. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.
Shu Y; He X; Wu P; Liu Y; Ding Y; Zhang Q
Front Public Health; 2022; 10():996179. PubMed ID: 36339230
[TBL] [Abstract][Full Text] [Related]
37. Once-Weekly Semaglutide in Adolescents with Obesity.
Weghuber D; Barrett T; Barrientos-Pérez M; Gies I; Hesse D; Jeppesen OK; Kelly AS; Mastrandrea LD; Sørrig R; Arslanian S;
N Engl J Med; 2022 Dec; 387(24):2245-2257. PubMed ID: 36322838
[TBL] [Abstract][Full Text] [Related]
38. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT; Batterham RL; Bhatta M; Buscemi S; Christensen LN; Frias JP; Jódar E; Kandler K; Rigas G; Wadden TA; Wharton S;
Nat Med; 2022 Oct; 28(10):2083-2091. PubMed ID: 36216945
[TBL] [Abstract][Full Text] [Related]
39. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.
Hu W; Song R; Cheng R; Liu C; Guo R; Tang W; Zhang J; Zhao Q; Li X; Liu J
Front Endocrinol (Lausanne); 2022; 13():927859. PubMed ID: 35898463
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
Mahapatra MK; Karuppasamy M; Sahoo BM
Pharm Res; 2022 Jun; 39(6):1233-1248. PubMed ID: 35650449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
